prikaz prve stranice dokumenta Liječenje malignog mezotelioma poplućnice
  Download
PDF 677.51 KB
Professional paper - Review paper
Liječenje malignog mezotelioma poplućnice
Medicina Fluminensis : Medicina Fluminensis, 45 (2009), 1; 94-101. urn:nbn:hr:184:711165
Cvitanović, Slavica; Kanceljak-Macan, Božica; Kotarac, Slava; Matanić, Dubravka; Vuković, Jonatan; Kardum, Goran

Cite this document

Cvitanović, S., Kanceljak Macan, B., Kotarac, S., Matanić, D., Vuković, J. & Kardum, G. (2009). Liječenje malignog mezotelioma poplućnice. Medicina Fluminensis : Medicina Fluminensis, 45. (1), 94-101. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:711165

Cvitanović, Slavica, et al. "Liječenje malignog mezotelioma poplućnice." Medicina Fluminensis : Medicina Fluminensis, vol. 45, no. 1, 2009, pp. 94-101. https://urn.nsk.hr/urn:nbn:hr:184:711165

Cvitanović, Slavica, Božica Kanceljak Macan, Slava Kotarac, Dubravka Matanić, Jonatan Vuković and Goran Kardum. "Liječenje malignog mezotelioma poplućnice." Medicina Fluminensis : Medicina Fluminensis 45, no. 1 (2009): 94-101. https://urn.nsk.hr/urn:nbn:hr:184:711165

Cvitanović, S., et al. (2009) 'Liječenje malignog mezotelioma poplućnice', Medicina Fluminensis : Medicina Fluminensis, 45(1), pp. 94-101. Available at: https://urn.nsk.hr/urn:nbn:hr:184:711165 (Accessed 22 November 2024)

Cvitanović S, Kanceljak Macan B, Kotarac S, Matanić D, Vuković J, Kardum G. Liječenje malignog mezotelioma poplućnice. Medicina Fluminensis : Medicina Fluminensis [Internet]. 2009 March 02 [cited 2024 November 22];45(1):94-101. Available at: https://urn.nsk.hr/urn:nbn:hr:184:711165

S. Cvitanović, B. Kanceljak Macan, S. Kotarac, D. Matanić, J. Vuković and G. Kardum, "Liječenje malignog mezotelioma poplućnice", Medicina Fluminensis : Medicina Fluminensis, vol. 45, no. 1, pp. 94-101, March 2009. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:711165. [Accessed: 22 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Liječenje malignog mezotelioma poplućnice
Title (english)Treatment of malignant pleural mesothelioma
AuthorSlavica Cvitanović
AuthorBožica Kanceljak-Macan
AuthorSlava Kotarac
AuthorDubravka Matanić
AuthorJonatan Vuković
AuthorGoran Kardum
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (croatian)
Cilj: Procijeniti učinkovitost kemoterapije u liječenju malignog mezotelioma poplućnice. Metode: U ovom radu retrospektivno je analizirana učinkovitost kemoterapije malignog mezotelioma poplućnice (MPM) u 29 oboljelih, liječenih u Klinici za plućne bolesti KB Split od 2002. – 2005. godine. Većina oboljelih 24/29, (82,7 %) bili su profesionalno izloženi azbestu. Liječenje je provedeno nakon što je patohistološkom imunohistokemijskom metodom dokazan podtip MPM. Rezultati: U 23/29 (79,3 %) oboljelih utvrđen je epiteloidni tip mezotelioma. Analizirani su rezultati liječenja u tri skupine oboljelih: 1. gemcitabin /cisplatin u prvoj liniji (PG protokol) u 6 oboljelih, 2. epirubicin / mitomicin u prvoj liniji (EM protokol) u 9 oboljelih, 3. suportivna terapija u 14 oboljelih koji su odbili kemoterapiju. Efikasnost terapije ocijenjena je definiranom stopom odgovora – response rate (RR) i izračunom krivulje preživljenja – mean survival (MS) prema preporukama WHO. Utvrđeni RR 33 % nije se razli- kovao između skupina liječenih PG i EM protokolom, ali je MS bolesnika liječenih EM protokolom u prvoj liniji znatno bolje od onih koji su liječeni PG protokolom ili suportivnom terapijom. Zaključak: Rezultati liječenja pokazuju da se EM protokolom postiže značajno bolje MS, nego PG protokolom. No, rezultati studije se slažu s rezultatima iz literature koji kazuju da je tumor kemorezistentan, te da je stopa tumorskog odgovora niska, a iznosi 10-30 % i bez značajnog utjecaja na MS.
Abstract (english)
Aim: To evaluate the effect of chemotherapy in treatment of patients with malignant pleural mesothelioma. Methods: The effectiveness of chemotherapy was evaluated in 29 patients with malignant pleural mesothelioma (MPM). The patients were treated in Clinical Hospital Split, University Hospital for Lung Diseases, between the years 2002-2005. 24/29 patients (82.7 %) were occupationally exposed to asbestos. Chemotherapy was applied after determination of MPM subtype by pathohystological immunohystochemistry. Results: Epitheloid mesothelioma was determined in 23/29 (79.3 %) patients. Results of treatment were analyzed separately in 6 patients treated with gemcitabine/cisplatine (PG protocol) in first line therapy, in 9 patients treated with epirubicine/mitomycine (EM protocol) in first line therapy, and in 14 patients who refused chemotherapy and were on supportive therapy. In accordance with WHO recommendations the evaluation of chemotherapy effectiveness by response rate (RR) and mean survival curve (MS) was done. RR was 33% in both groups: those on PG and EM protocol, but MS was significantly better in patients treated with EM protocol in the first line chemotherapy comparing to PG protocol and supportive care. Conclusions: The EM protocol has better MS results then PG protocol treatment. However, this study have confirmed the chemo resistance of the tumor, low response rate to the chemotherapy (only 10-30 %), without significant influence to MS.
Keywords (croatian)
Keywords (english)
Languagecroatian
Publication typeProfessional paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina Fluminensis : Medicina Fluminensis
Numberingvol. 45, no. 1, pp. 94-101
p-ISSN0025-7729
URN:NBNurn:nbn:hr:184:711165
Publication2009-03-02
Document URLhttp://hrcak.srce.hr/34715
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-05-03 07:58:24